查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994144

診斷試劑市場：按產品類型、最終用戶和應用分類的全球市場預測，2026-2032年

Diagnostic Substances Market by Product Type, End-User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，診斷試劑市值將達到 1,895.3 億美元，到 2026 年將成長至 2,014 億美元，到 2032 年將達到 2,984.7 億美元，複合年成長率為 6.70%。

主要市場統計數據
基準年 2025 1895.3億美元
預計年份：2026年 2014億美元
預測年份 2032 2984.7億美元
複合年成長率 (%) 6.70%

本檢驗了技術創新、臨床效用預期以及策略供應鏈的需求，概述了目前的診斷試劑市場格局。

在科學創新、臨床實務轉變和監管力度加大的推動下，診斷領域正經歷快速變革時期。分子診斷、影像技術和高通量檢測技術的進步正在重塑臨床醫生、檢查室和研究機構識別和監測疾病的方式。同時，支付方和採購團隊也越來越重視臨床效用和營運效率的證據，這迫使製造商和服務供應商展現出超越分析能力的清晰價值提案。

科學突破、數位整合、監管演變和支付方需求如何從整體上重塑競爭和價值創造的結構。

科學突破、數位融合以及相關人員期望的轉變正在重塑產業格局。精準的分子診斷工具和先進的成像系統能夠更早、更特異性檢測疾病，從而帶動了對配套試劑盒、檢測方法和支持靶向工作流程的專用試劑的需求成長。同時，數位健康平台和實驗室資訊系統 (LIS) 正在改進數據收集和分析，使醫療服務提供者能夠利用診斷結果來支持決策並推動社區健康計畫。

評估近期美國關稅政策對診斷供應鏈和採購韌性的營運和策略影響。

美國實施的關稅措施為營運全球供應鏈並服務於國內終端用戶的公司帶來了新的挑戰。某些類型的檢測設備、試劑和進口零件關稅的提高推高了整體成本，促使買家重新評估其籌資策略。為此，許多供應商開始調整採購結構，包括供應商多元化、增加區域庫存緩衝以及重新談判供應商契約，以在維持服務水準的同時保護利潤率。

我們透過產品類型、最終用戶環境以及臨床和研究應用等多層次細分來分析市場，並確定策略轉折點。

一套精細的細分框架揭示了競爭優勢和未滿足需求的集中領域，並按產品類型、最終用戶和應用進行細分。在檢驗產品類型差異時，儀器被細分為分析儀器、影像儀器和分子診斷儀器，其中分子診斷儀器包括次世代定序平台和PCR儀器。試劑盒和檢測方法包括ELISA試劑盒、橫向流動化驗、PCR試劑盒和快速檢測套組，每種試劑盒都針對不同的應用場景，從集中式檢查室到分散式檢查。試劑構成一個獨立的支柱，包括抗體試劑、抗原試劑、酵素、核酸試劑和重組蛋白，它們共同支撐著檢測方法的性能和可重複性。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和商業化需求比較決定了其採用和監管參與程度。

區域趨勢持續影響美洲、歐洲、中東和非洲以及亞太地區的需求模式、監管方式和投資重點。在美洲，一體化醫療保健系統和大規模檢查室網路正在推動對擴充性設備、整合檢測組合以及支援報銷的基於價值的證據的需求。此外，該地區對公共衛生緊急準備的重視也影響快速檢測套組和高通量分析儀的採購。

主要企業如何調整在技術、製造和服務方面的投資，以確保永續的商業性競爭力以及與機構的夥伴關係？

診斷生態系中的企業策略正日益沿著技術深度、上游工程試劑管理和以服務為導向的商業化這三大維度呈現差異化趨勢。領先的儀器製造商正投資於平台互通性、軟體驅動的診斷以及拓展服務組合，以建立長期的客戶關係。同時，專業試劑供應商則專注於高品質的原料和生產的一致性，因為他們意識到監管機構和臨床使用者對檢測結果的可重複性要求越來越嚴格。

為產業領導者提供切實可行的策略步驟，以增強韌性、加速普及，並在診斷領域實現永續的商業性差異化。

產業領導者應優先考慮一系列關鍵舉措，以應對不確定性並抓住策略機會。首先，投資於提升製造韌性和供應商多元化可以降低貿易政策波動和零件短缺帶來的風險，同時保障臨床客戶的持續供應。其次，加強監管和臨床證據能力可以加快企業在複雜法律制度下進入市場的速度，並為保險公司提供保險決策所需的必要數據。第三，將從連接性和分析到遠端監控等數位化功能整合到儀器和流程中，可以創造永續的收入來源並提高客戶維繫留存率。

結合一手訪談、監管分析和價值鏈映射的綜合調查方法，確保了嚴謹且檢驗的見解。

本分析整合了來自一手和二手調查的數據，以提供關於診斷試劑的全面觀點。一手數據包括對檢查室經理、採購主管、法規專家和產品開發負責人的結構化訪談，從而獲得關於應用促進因素、營運挑戰和採購重點的實地洞察。這些定性資訊與同行評審文獻、監管指導文件和公司披露等二級資訊來源進行交叉核對，以確保事實準確性和背景深度。

最終的綜合分析強調了技術卓越性、監管合規性和臨床效用之間的協調一致是決定未來成功的關鍵因素。

診斷樣本處於技術創新與臨床需求的交匯點，該領域的短期發展趨勢將取決於企業能否將產品功能與實際臨床和營運需求完美契合。隨著對臨床效用、供應鏈韌性和合規性的日益重視，新參與企業的門檻不斷提高，而能夠展現端到端可靠性的企業則獲得了豐厚的回報。同時，數位化和整合服務模式的進步正在為企業創造超越單純交易的長期客戶參與新途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 診斷試劑市場：依產品類型分類

  • 裝置
    • 分析器
    • 影像設備
    • 分子診斷設備
      • 次世代定序
      • PCR裝置
  • 試劑盒和檢測方法
    • ELISA試劑盒
    • 橫向流動化驗
    • PCR試劑盒
    • 快速檢測套組
  • 試劑
    • 抗體試劑
    • 抗原試劑
    • 酵素
    • 核酸試劑
    • 重組蛋白

第9章 診斷試劑市場：依最終用戶分類

  • 診斷檢查室
  • 法醫學研究所
  • 醫院和診所
  • 即時偵測設施
  • 研究和學術機構

第10章 診斷試劑市場：依應用領域分類

  • 臨床診斷
    • 循環系統
    • 內分泌學
    • 感染疾病
    • 神經病學
    • 腫瘤學
  • 法醫學
    • 血液檢體檢測
    • DNA分析
    • 毒理學
  • 研究
    • 藥物發現
    • 基因組調查
    • 蛋白質體學研究

第11章 診斷試劑市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 診斷試劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 診斷試劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國診斷試藥市場

第15章：中國診斷試劑市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Asuragen, Inc. by Bio-Techne Corporation
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • bioLytical Laboratories
  • bioMerieux SA
  • Cepheid by Danaher Corporation
  • DiaSorin SpA
  • Enzo Biochem, Inc.
  • Hitachi Ltd.
  • Hoffmann-La Roche AG
  • Hologic Inc.
  • HyTest Ltd.
  • Illumina Inc.
  • Merck KGaA
  • OraSure Technologies, Inc.
  • Ortho Clinical Diagnostics
  • Qiagen NV
  • Quidel Corporation
  • Randox Laboratories Ltd.
  • Sekisui Diagnostics, LLC
  • Siemens AG
  • Sysmex Corporation by TOA Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-1A1A064C040C

The Diagnostic Substances Market was valued at USD 189.53 billion in 2025 and is projected to grow to USD 201.40 billion in 2026, with a CAGR of 6.70%, reaching USD 298.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 189.53 billion
Estimated Year [2026] USD 201.40 billion
Forecast Year [2032] USD 298.47 billion
CAGR (%) 6.70%

Framing the current diagnostic substances environment by examining technological innovation, clinical utility expectations, and strategic supply chain imperatives

The diagnostic substances arena is undergoing a period of rapid evolution driven by scientific innovation, shifting clinical practice, and heightened regulatory scrutiny. Technological advances in molecular diagnostics, imaging modalities, and high-throughput assay formats are reshaping how clinicians, laboratories, and research organizations identify and monitor disease. At the same time, payers and procurement teams are placing greater emphasis on evidence of clinical utility and operational efficiency, which is prompting manufacturers and service providers to demonstrate clear value propositions beyond analytical performance.

Across laboratory networks and point-of-care settings, operational resilience and supply chain continuity have ascended as strategic priorities. Stakeholders are balancing the imperative to adopt cutting-edge instruments and assays with the need to ensure reproducibility, affordability, and regulatory compliance. Consequently, partnerships among instrument makers, reagent suppliers, and clinical networks are becoming more integrated, with cross-functional collaborations focused on workflow optimization, data interoperability, and lifecycle support. Taken together, these dynamics are recalibrating investment decisions and competitive positioning in diagnostic substances, creating new opportunities for organizations that can translate technical differentiation into measurable clinical and economic outcomes.

How scientific breakthroughs, digital integration, regulatory evolution, and payer demands are collectively reshaping competitive dynamics and value creation

The landscape is being transformed by a confluence of scientific breakthroughs, digital integration, and shifting stakeholder expectations. Precision-focused molecular tools and advanced imaging systems are enabling earlier and more specific detection of disease, which in turn is driving demand for complementary kits, assays, and specialized reagents that can support targeted workflows. Simultaneously, digital health platforms and laboratory information systems are improving data capture and analytics, enabling providers to harness diagnostic outputs for decision support and population health initiatives.

Regulatory frameworks are also evolving to accommodate novel modalities and accelerate review pathways for high-impact diagnostics, which creates both opportunities and compliance challenges for manufacturers. Payers are increasingly requiring evidence of clinical and economic benefit, prompting firms to invest in real-world evidence generation and post-market surveillance. Finally, market participants are responding to procurement pressures by redesigning service models and aftersales support, prioritizing total cost of ownership and uptime guarantees. Collectively, these trends are shifting competitive dynamics toward vertically integrated solutions and strategic alliances that can deliver end-to-end value to laboratories, hospitals, and research institutions.

Assessing the operational and strategic ramifications of recent United States tariff policies on diagnostic supply chains and procurement resilience

Tariff actions implemented in the United States have introduced new layers of complexity for firms operating global supply chains and servicing domestic end-users. Increased duties on specific classes of laboratory instruments, reagents, and imported components have elevated landed costs and prompted buyers to reassess sourcing strategies. In response, many suppliers have initiated changes to procurement, including diversifying supplier bases, increasing regional inventory buffers, and renegotiating supplier contracts to protect margins while preserving service levels.

These shifts have also accelerated conversations around onshoring and nearshoring of critical manufacturing and subassembly capabilities. Manufacturers and contract providers are weighing the trade-offs between higher fixed investments for domestic capacity and the resilience benefits that come from reduced exposure to cross-border tariff volatility. At the same time, downstream stakeholders-diagnostic laboratories, hospitals, and point-of-care providers-are adapting procurement protocols to account for longer lead times and potential component substitution. This environment reinforces the importance of transparent supplier communication, contractual flexibility, and scenario planning to mitigate the cumulative operational impacts of tariff-induced cost pressures while maintaining clinical continuity.

Deconstructing the market through layered segmentation across product types, end-user settings, and clinical and research applications to identify strategic inflection points

A nuanced segmentation framework reveals where competitive advantages and unmet needs are concentrated across product types, end-users, and applications. When examining product type distinctions, instruments are subdivided into analyzers, imaging equipment, and molecular diagnostic instruments, with the latter category encompassing next-generation sequencing platforms and PCR machines. Kits and assays include ELISA kits, lateral flow assays, PCR kits, and rapid test kits, each serving distinct use cases from centralized laboratories to decentralized testing. Reagents form a separate pillar and comprise antibody reagents, antigen reagents, enzymes, nucleic acid reagents, and recombinant proteins, which collectively underpin assay performance and reproducibility.

Turning to end-user segmentation, diagnostic laboratories and forensic laboratories demand high-throughput, validated solutions with robust quality management and chain-of-custody capabilities, whereas hospitals and clinics prioritize integrated workflows and clinician-facing usability. Point-of-care testing facilities emphasize portability, speed, and simplicity, and research and academic institutes focus on versatility and advanced methodological support. Regarding applications, clinical diagnostics spans cardiology, endocrinology, infectious diseases, neurology, and oncology, each with unique biomarker requirements and regulatory pathways. Forensic applications center on blood sample testing, DNA analysis, and toxicology, while research applications include drug discovery, genomics research, and proteomics research. This layered segmentation highlights where product innovation, regulatory navigation, and tailored go-to-market strategies can yield the greatest returns for suppliers and service providers.

Comparative regional dynamics and commercialization imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine adoption and regulatory engagement

Regional dynamics continue to shape demand patterns, regulatory approaches, and investment priorities across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated healthcare systems and large laboratory networks create demand for scalable instrumentation, integrated assay portfolios, and value-based evidence that supports reimbursement. The region also emphasizes public health preparedness, which influences procurement of rapid test kits and high-throughput analyzers.

Europe, Middle East & Africa features a mosaic of regulatory regimes and reimbursement landscapes, where harmonization initiatives coexist with national-level variability. This environment elevates the importance of local regulatory expertise, adaptable product configurations, and partnerships that can navigate fragmented reimbursement pathways. Asia-Pacific is characterized by rapid adoption of molecular diagnostics and point-of-care modalities, driven by large patient volumes, robust research activity, and government-led health modernization programs. Across regions, manufacturers are balancing global platform strategies with localized commercialization tactics to address distinct clinical priorities, regulatory hurdles, and infrastructure constraints.

How leading companies are aligning technological, manufacturing, and service investments to secure durable commercial advantages and institutional partnerships

Company strategies in the diagnostic substances ecosystem are differentiating along axes of technological depth, upstream reagent control, and service-oriented commercialization. Leading instrument manufacturers are investing in platform interoperability, software-enabled diagnostics, and expanded service portfolios to lock in long-term customer relationships. At the same time, specialized reagent providers are focusing on high-quality raw materials and manufacturing consistency, recognizing that reproducibility of assays is increasingly scrutinized by regulators and clinical users.

Strategic partnerships and M&A activity continue to be tools for filling capability gaps, whether to add molecular expertise, expand geographic reach, or secure critical reagent supply lines. Contract manufacturing and co-development agreements are increasingly common, enabling smaller innovators to scale while leveraging established quality systems. Firms that combine robust regulatory pathways, strong technical support, and flexible commercial terms are better positioned to capture long-term institutional contracts and to support multi-site deployments. Overall, the competitive landscape rewards companies that deliver end-to-end value-combining validated chemistry, reliable instruments, and responsive lifecycle services.

Actionable strategic moves for industry leaders to strengthen resilience, accelerate access, and create sustainable commercial differentiation in diagnostics

Industry leaders should prioritize a set of focused actions to navigate uncertainty and capture strategic opportunities. First, investing in manufacturing resilience and supplier diversification can reduce exposure to trade policy shocks and component shortages while supporting continuity for clinical customers. Second, strengthening regulatory and clinical evidence capabilities will accelerate market access in complex jurisdictions and provide payers with the data required for coverage decisions. Third, embedding digital capabilities into instruments and assays-ranging from connectivity and analytics to remote monitoring-can create recurring revenue streams and improve customer retention.

Moreover, companies should pursue targeted collaborations with healthcare providers and academic centers to generate real-world evidence and to refine product-market fit for specialized applications like oncology and genomics research. Commercial teams must also adapt contracting approaches to emphasize service-level agreements and outcome-based elements that resonate with procurement stakeholders. Finally, leaders should maintain agile scenario planning processes to respond quickly to policy shifts and supply chain disruptions, ensuring that operational and commercial tactics remain aligned with evolving market realities.

Comprehensive research methodology combining primary interviews, regulatory analysis, and value-chain mapping to ensure rigorous and validated findings

This analysis synthesizes primary and secondary research streams to deliver a comprehensive perspective on diagnostic substances. Primary inputs include structured interviews with laboratory directors, procurement executives, regulatory specialists, and product development leaders, providing frontline insights into adoption drivers, operational pain points, and procurement priorities. These qualitative inputs were triangulated with secondary sources such as peer-reviewed literature, regulatory guidance documents, and corporate filings to ensure factual rigor and contextual depth.

Analytical approaches included value-chain mapping to identify critical bottlenecks, scenario analysis to evaluate tariff- and supply-related risks, and comparative regional assessments to surface localization requirements. Attention was given to methodological transparency: stakeholders and data sources were chosen to reflect a balance of public and private sector perspectives, and assumptions underlying interpretive judgments are documented in the full report. Where applicable, findings were validated through peer review by subject-matter experts in molecular diagnostics, clinical laboratory operations, and health economics.

Final synthesis emphasizing alignment of technical excellence, regulatory compliance, and real-world utility as the decisive determinants of future success

Diagnostic substances are at the intersection of technological innovation and clinical necessity, and the sector's near-term trajectory will be governed by how well firms align product capabilities with real-world clinical and operational needs. Increasing emphasis on evidence of clinical utility, supply chain resilience, and regulatory adherence is raising the bar for new entrants while rewarding companies that can demonstrate end-to-end reliability. At the same time, digital enablement and integrated service models are creating new touchpoints for long-term customer engagement beyond transactional sales.

To succeed, stakeholders must balance investment in advanced platforms and reagent quality with pragmatic strategies for regional market access and procurement engagement. Proactive collaboration across manufacturers, clinical networks, and regulatory bodies will be essential to streamline adoption pathways and to capture the full potential of diagnostics for patient care and research advancement. Ultimately, organizations that can translate technical differentiation into measurable clinical outcomes and operational value will lead the next wave of growth and adoption in diagnostic substances.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diagnostic Substances Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Analyzers
    • 8.1.2. Imaging Equipment
    • 8.1.3. Molecular Diagnostic Instruments
      • 8.1.3.1. Next-Generation Sequencing
      • 8.1.3.2. PCR Machines
  • 8.2. Kits & Assays
    • 8.2.1. ELISA Kits
    • 8.2.2. Lateral Flow Assays
    • 8.2.3. PCR Kits
    • 8.2.4. Rapid Test Kits
  • 8.3. Reagents
    • 8.3.1. Antibody Reagents
    • 8.3.2. Antigen Reagents
    • 8.3.3. Enzymes
    • 8.3.4. Nucleic Acid Reagents
    • 8.3.5. Recombinant Proteins

9. Diagnostic Substances Market, by End-User

  • 9.1. Diagnostic Laboratories
  • 9.2. Forensic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Point-of-Care Testing Facilities
  • 9.5. Research & Academic Institutes

10. Diagnostic Substances Market, by Application

  • 10.1. Clinical Diagnostics
    • 10.1.1. Cardiology
    • 10.1.2. Endocrinology
    • 10.1.3. Infectious Diseases
    • 10.1.4. Neurology
    • 10.1.5. Oncology
  • 10.2. Forensic
    • 10.2.1. Blood Sample Testing
    • 10.2.2. DNA Analysis
    • 10.2.3. Toxicology
  • 10.3. Research
    • 10.3.1. Drug Discovery
    • 10.3.2. Genomics Research
    • 10.3.3. Proteomics Research

11. Diagnostic Substances Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Diagnostic Substances Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Diagnostic Substances Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Diagnostic Substances Market

15. China Diagnostic Substances Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Agilent Technologies Inc.
  • 16.7. Asuragen, Inc. by Bio-Techne Corporation
  • 16.8. Becton, Dickinson and Company
  • 16.9. Bio-Rad Laboratories Inc.
  • 16.10. bioLytical Laboratories
  • 16.11. bioMerieux SA
  • 16.12. Cepheid by Danaher Corporation
  • 16.13. DiaSorin S.p.A.
  • 16.14. Enzo Biochem, Inc.
  • 16.15. Hitachi Ltd.
  • 16.16. Hoffmann-La Roche AG
  • 16.17. Hologic Inc.
  • 16.18. HyTest Ltd.
  • 16.19. Illumina Inc.
  • 16.20. Merck KGaA
  • 16.21. OraSure Technologies, Inc.
  • 16.22. Ortho Clinical Diagnostics
  • 16.23. Qiagen N.V.
  • 16.24. Quidel Corporation
  • 16.25. Randox Laboratories Ltd.
  • 16.26. Sekisui Diagnostics, LLC
  • 16.27. Siemens AG
  • 16.28. Sysmex Corporation by TOA Corporation
  • 16.29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY IMAGING EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIBODY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ANTIGEN REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NUCLEIC ACID REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY POINT-OF-CARE TESTING FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY BLOOD SAMPLE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DNA ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GENOMICS RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PROTEOMICS RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 203. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 221. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 224. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 225. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 226. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 227. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 229. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 231. GCC DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 254. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 258. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 259. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 260. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 261. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 263. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 264. G7 DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 265. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 266. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 268. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 270. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 271. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 272. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 274. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 275. NATO DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL DIAGNOSTIC SUBSTANCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY MOLECULAR DIAGNOSTIC INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY KITS & ASSAYS, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY REAGENTS, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY FORENSIC, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA DIAGNOSTIC SUBSTANCES MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)